Allogeneic Mesenchymal Stem Cell Therapy For Dry Eye Disease In Patients With Sjögren's Syndrome: A Randomized Clinical Trial

This double-blinded randomized clinical trial (RCT) aimed to evaluate the efficacy of injecting allogeneic adipose-derived mesenchymal stem cells (ASCs) into the lacrimal gland (LG) for the treatment of dry eye disease (DED) secondary to Sjögren's syndrome (SS).

The RCT was conducted at the Copenhagen University Hospital – Rigshospitalet, Denmark, according to the Declaration of Helsinki and the ICH-GCP Guideline, from November 2020 to December 2022.

Fifty-four participants with severe DED secondary to SS were included and allocated to either ASCs (n=20), vehicle (n=20), or a non-randomized observation group (n=14). The intervention groups received a single injection of either ASCs or an active comparator (vehicle, Cryostor® CS10) into the LG in one eye, while the observation group received lubricating eye drops only. The primary outcome measure was changes in Ocular Surface Disease Index (OSDI) score and secondary outcome measures were non-invasive tear break-up time, tear meniscus height, Schirmer’s test, and Oxford score within a 12-month follow-up.

A significant reduction in OSDI score was observed in the ASCs and vehicle groups compared to the observation group. In addition, the ASCs group demonstrated a significant increase in non-invasive tear break-up time compared to the vehicle group at the 4-week follow-up and to the observation group at the 12-month follow-up. A significant improvement in ocular surface staining, tear osmolarity, and Schirmer test score from baseline was also observed in the ASCs group; however, these changes were not significant compared to the other groups.

Improvement of subjective and objective signs and symptoms of DED was observed in both intervention groups following injection into the LG compared to the observation group. Future studies should investigate the mode-of-action of both injection treatments.